Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-11-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司第三届董事会2025年第五次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the company's third board of directors' fifth extraordinary meeting in 2025. It details the meeting date, attendance, and voting results on several agenda items related to the company's restricted stock incentive plan. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and approvals. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The content fits best under Board/Management Information (MANG) as it concerns board meeting resolutions and management decisions.
2025-11-28 Chinese
圣湘生物科技股份有限公司董事会薪酬与考核委员会关于2023年第二期限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
Remuneration Information Classification · 95% confidence The document is a verification opinion from the Board's Remuneration and Assessment Committee regarding the first vesting list of a restricted stock incentive plan for 2023. It references relevant laws and regulations about stock incentives and the company's articles of association. The content focuses on the eligibility and qualification of incentive recipients and the status of the stock incentive plan's vesting. This is a detailed report related to executive compensation and stock incentive plans, which aligns with Remuneration Information filings. The document is short but contains substantive content about compensation and stock incentives, not merely an announcement or a certification. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2025-11-28 Chinese
圣湘生物科技股份有限公司关于作废2023年第二期限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from the board of directors of 圣湘生物科技股份有限公司 regarding the cancellation of certain unvested restricted shares under the company's 2023 second phase restricted stock incentive plan. It details the decision-making process, approvals, and legal opinions related to the cancellation of these shares. The document does not contain financial statements or detailed financial performance data but rather focuses on corporate governance and management decisions related to stock incentives. This type of announcement fits the category of Board/Management Information (MANG), as it concerns decisions made by the board about management incentives and stock plans.
2025-11-28 Chinese
圣湘生物科技股份有限公司关于调整2023年第二期限制性股票激励计划授予价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the company regarding the adjustment of the grant price of a restricted stock incentive plan for 2023. It details board and shareholder meetings, approvals, and legal opinions related to the stock incentive plan. The content focuses on changes to the stock incentive plan's grant price due to dividends and other equity events. It is not a full financial report, earnings release, or management discussion, but rather a specific corporate announcement about stock incentive plan adjustments. This fits best under Capital/Financing Update (CAP) as it relates to changes in equity compensation plans and their pricing, which affects the company's capital structure and financing arrangements. The document length is 3460 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2025-11-28 Chinese
圣湘生物科技股份有限公司关于2023年第二期限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement from 圣湘生物科技股份有限公司 regarding the first vesting period of the company's 2023 second restricted stock incentive plan. It includes specifics about the number of shares vested, the vesting schedule, performance conditions, individual and company-level performance requirements, and the approval process by the board and supervisory committees. It also discusses the legal opinions and accounting treatment related to the stock incentive plan. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is not related to earnings releases, mergers, or voting results. Instead, it is a disclosure about the company's stock incentive plan and the vesting of restricted shares, which falls under remuneration information related to executive and employee compensation plans. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length (9675 characters) and detailed content support this classification with high confidence.
2025-11-28 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第二期限制性股票激励计划调整授予价格、首次授予部分第一个归属期符合归属条件及作废部分限制性股票相关事项的法律意见书
Regulatory Filings
2025-11-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.